Condition
NK Cell Mediated Immunity
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Early P 1 (1)
P 1 (2)
Trial Status
Unknown3
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT04377113CompletedPrimary
Cellular Immunity and Renal Cell Cancer
NCT03662477Early Phase 1UnknownPrimary
Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation
NCT03948828Phase 1UnknownPrimary
Clinical Study of NK Cells in the Treatment of Severe Endometriosis
NCT03554889Phase 1Unknown
Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
Showing all 4 trials